Texas Genetics Lab and Former Executives Pay $36.4m to Settle Kickback Allegations

• A Texas genetic testing laboratory and two individuals have agreed to pay $36.4m to resolve allegations that the company paid unlawful commissions and kickbacks to generate business, while the laboratory has entered a five-year corporate integrity agreement with the US government.

Access DX, a Houston-based genetic testing laboratory, has agreed to a $36.4m settlement with the US government over allegations that it violated the False Claims Act by paying commissions and other remuneration linked to the referral of genetic testing business.

The settlement, announced on 12 August, also involves the company’s former chief executive officer and a businessman who was alleged to have played a role in the arrangement. The company has agreed to a five-year corporate integrity agreement requiring it to strengthen its compliance programme and appoint a compliance officer.

The case centres on allegations that Access DX used financial incentives to induce referrals for genetic testing services. Under US healthcare fraud laws, payments intended to generate referrals for services reimbursed by federal healthcare programmes can create significant anti-kickback and False Claims Act exposure.

The government’s settlement with the company does not constitute a criminal conviction. The allegations were resolved through the civil settlement, without a determination of liability by the court.

Compliance programme placed under scrutiny

The most significant compliance consequence may extend beyond the $36.4m financial settlement.

As part of the resolution, Access DX has agreed to enter into a five-year corporate integrity agreement with the Department of Health and Human Services Office of Inspector General.

The agreement requires the laboratory to appoint a compliance officer and implement enhanced compliance measures.

Corporate integrity agreements are a common enforcement tool used by US healthcare regulators following allegations of fraud and other compliance failures. Rather than simply imposing a financial penalty, they require organisations to demonstrate that they have strengthened their compliance infrastructure and introduced controls designed to prevent similar conduct from recurring.

For compliance professionals, that distinction is important.

A settlement addresses the alleged misconduct that has already occurred. A corporate integrity agreement is intended to address the control environment that allowed the alleged conduct to occur in the first place.

The referral risk

Genetic testing has become a significant area of healthcare enforcement because laboratories often depend on referrals from physicians, healthcare providers and other intermediaries.

That creates a structural compliance risk.

Where payment is linked to the volume or value of referrals, an arrangement that may appear commercially attractive can quickly become a regulatory problem if the remuneration is intended to influence referrals for services paid for by government healthcare programmes.

The central compliance question is therefore not simply whether money changed hands.

It is why the payment was made, who received it, what services were actually provided and whether the payment was connected to the generation of federally reimbursed healthcare business.

Why third-party arrangements matter

The case also illustrates the importance of third-party risk management.

Healthcare companies frequently rely on independent contractors, marketing organisations, consultants and referral partners to generate business. Those relationships can create compliance exposure even where the company’s own employees are not directly making improper payments.

Effective oversight requires organisations to understand who is being paid, why they are being paid, how compensation is calculated and whether the underlying services can be independently verified.

A contract alone does not eliminate the risk.

If a third party is compensated according to the number or value of referrals generated, compliance teams need to understand whether the arrangement creates an incentive that could conflict with healthcare anti-kickback requirements.

The cost of weak controls

The $36.4m settlement demonstrates the potential financial consequences of inadequate controls in a highly regulated industry.

But the financial penalty is only one component of the exposure.

A corporate integrity agreement can impose years of additional oversight, reporting requirements and compliance investment. Management must dedicate resources to implementing the agreement, monitoring compliance and demonstrating that controls are operating effectively.

The reputational consequences can also extend beyond the settlement itself.

For healthcare organisations, allegations involving referral payments can affect relationships with regulators, customers, investors and business partners even after a matter has been resolved.

A broader warning for healthcare compliance

The Access DX settlement is another reminder that healthcare companies cannot treat sales and compliance as separate functions.

Revenue-generation arrangements need to be reviewed through a compliance lens, particularly where compensation depends on referrals, patient volume or government-reimbursed services.

The more commercially valuable a referral relationship becomes, the more important it is to understand the regulatory basis for the underlying payment.

For compliance officers, the lesson is straightforward: referral arrangements should be scrutinised before they become revenue streams, not after regulators begin asking questions.

Access DX’s five-year corporate integrity agreement will now put its compliance framework under sustained scrutiny.

The settlement therefore closes the government’s immediate enforcement action while opening a new test for the laboratory: whether its strengthened controls can prevent the type of conduct alleged in the case from happening again.